Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its Growth Portfolio and continued to optimize its cost structure. In the back half, Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing transformational medicines and delivering on its Growth Portfolio and important pipeline opportunities to shape the growth trajectory. Growth Portfolio revenues came in at $6.6 billion, reflecting 18% growth. This was mainly due to its immuno-oncology (IO) portfolio, Breyanzi, Reblozyl, and Camzyos, and reflects the strength of Cobenfy.

Bristol-Myers Squibb Company (NYSE:BMY) increased its FY 2025 non-GAAP revenue guidance from a ~$45.8 billion – $46.8 billion to ~$46.5 billion – $47.5 billion. This reflects the strength of its Growth Portfolio, better-than-anticipated Legacy Portfolio sales in Q2 2025, and a favorable impact of ~$200 million associated with foreign exchange rates. Bristol-Myers Squibb Company (NYSE:BMY) expects its non-GAAP EPS to be between $6.35 – $6.65.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.